SCHEMBL29655018

SCHEMBL29655018

Cc1ccc2cn[nH]c(=O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.56
PARP1 P09874 3/20 0.56
HSD17B10 Q99714 2/20 0.56
PRKCI P41743 1/20 0.56
PDE4B Q07343 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 4/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 2/20 0.43
TYMS P04818 1/20 0.43
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
CHEK1 O14757 2/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13488080 1.00 ALDH1A1 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL1008698 0.85 ALDH1A1 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL31538179 0.79 MAPT (0.58) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL4702841 0.79 MAPT (0.58) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL392303 0.78 METAP2 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL29599162 0.78 METAP2 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL26427164 0.78 PARP1 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL29390884 0.78 PARP1 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL21917350 0.78 PARP1 (0.56) ALDH1A1PARP1HSD17B10PRKCIPDE4B
SCHEMBL1526819 0.77 ALDH1A1 (0.51) ALDH1A1PARP1HSD17B10PRKCIPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 CN disclosed